Last reviewed · How we verify
Rotigotine Transdermal System
At a glance
| Generic name | Rotigotine Transdermal System |
|---|---|
| Also known as | Neupro |
| Sponsor | Inflamax Research Incorporated |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder (PHASE2)
- Adhesion and Safety of Rotigexole Compared to Neupro® (NA)
- A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease (PHASE3)
- Dopaminergic Therapy for Frontotemporal Dementia Patients (PHASE2)
- Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease (PHASE2)
- A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome (PHASE3)
- A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause (PHASE3)
- Butrans for Treatment of Restless Legs Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |